Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: medsunman who wrote (11167)	11/15/1997 2:50:00 PM
From: Henry Niman	Respond to of 32384

medsunman, I had actually been invited to the AMLN thread to comment on the Phase III results. I indicated that the street would not like it. They did not. I also indicated that the results would lead to delays. Last week AMLN admitted that there would be 12-18 month delays. My comments on AMLN were right on the money, but the posters elected to shoot the "invited" messenger. Shortly thereafter, AMLN posters began posting on LGND.

To: medsunman who wrote (11167)	11/15/1997 3:08:00 PM
From: JOHN W.	Read Replies (1) \| Respond to of 32384

Henry, has several problems with fully disclosing the facts and would provide self serving propaganda that has no effect on the LGND stock, if anything takes away from it. He brags he has been here since 1992, singing the same praises that never materialize. For all looking at LGND as a long term investment pleas look at their 5 yr price history, essentially you can buy LGND now at the same price as you could have bought this company in 1992. quote.yahoo.com When is this breakout? Compare this to the 5 yr history of a company that has a proven record of producing block buster drugs, getting FDA approval, , effectively employind a sales force and marketing team. That has a pipeline of several cancer drugs in Phase I, Phase II/III trials, including drugs in diabetes, obesity, pain, cure for the common cold, hepatitis C, Herpes, and additional AIDS drugs. Now henry that is a pipeline. quote.yahoo.com Some of their science is interesting, however tey will never generate revenues that will propel their stock to levels of the current profitable Biotech companies that are as rare as factual info from Henry. IMHO, Biotechs are extremely risky, non-profitable Biotechs are very susceptible to further downturns in this market. When does anyone think this company will become profitable, 2000 or 2001, maybe never. I can assure Henry, that in the mean time, as the small bones that Lily will pay will not offset an extremely high and disproportionate burn rate which will only lead to one thing, analyst fighting over themselves to get the next offering. How many share will this company offer as they continue to dillute the current shareholders value. This is the wrong environment to be investing in a company that continues to lose money. IMHO, an investment in AMGN provides much more opportunity without the risk that biotechs that will be in the red until the next century, and that considers that everything goes perfectly for LGND with their pipeline, a company that has problems with their dealings with Big Pharma partnerships. Pfizer.